Evidence map›Paper›PMID 28625817›Full record

SynthesisClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2018

Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review.

Mathurin Fumery, Siddharth Singh, Parambir S Dulai, Corinne Gower-Rousseau, Laurent Peyrin-Biroulet, William J Sandborn

Registry-linked trialOpen access · bronzeAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05912712 (Safety And Efficacy Study of Autologous Platelet-rich Plasma), which is not on this map. Cited by 231 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
231citing papers in PubMed, 10 pooled it
22.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05912712 phase1unknown statusnot on this mapstarted 2023, after this paper: background citation

Safety And Efficacy Study of Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum for the Topical Treatment of Rectal Mucosal Ulcers

TypeinterventionalSponsorXijing Hospital of Digestive DiseasesRan2023 to 2025Enrolled60ConditionsUlcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe, Rectal UlcerArmsAutologous Platelet-rich Plasma (PRP) and Thrombin Coagulum Treatment, Autologous Platelet-poor Plasma (PPP) and Thrombin Coagulum Treatment, Mesalazine Suppository Treatment, Infliximab Treatment
3 · Its place in the literature

Who cites it

231 citing papers in PubMed, 10 syntheses or guidelines pooled it, 476 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020
    Pooled it
  11. Trial
  12. Trial
  13. Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Trial
  14. Trial
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

171 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Mathurin FumeryDivision of Gastroenterology, University of California San Diego, La Jolla, California; Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Amiens, France. Electronic address: mathurinfumery@gmail.com.
Siddharth SinghDivision of Gastroenterology, University of California San Diego, La Jolla, California; Division of Biomedical Informatics, University of California San Diego, La Jolla, California.
Parambir S DulaiDivision of Gastroenterology, University of California San Diego, La Jolla, California.
Corinne Gower-RousseauLIRIC Inserm, Unit 995, Lille University, Lille, France; Epidemiology Unit, Epimad Registry, Lille University Hospital, France.
Laurent Peyrin-BirouletGastroenterology Unit, Inserm U954, Nancy University and Hospital, Nancy, France.
William J SandbornDivision of Gastroenterology, University of California San Diego, La Jolla, California.
University of California San Diego · USInserm · FR

Funding

San Diego Biomedical Informatics Education & Research (SABER)T15LM011271 · NLM · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHAMIM NEMATI · 2012 to 2026
$9.7M
Training Grant in GastroenterologyT32DK007202 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 1985 to 2022
$7.7M
Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel DiseasesK23DK117058 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SINGH, SIDDHARTH · 2018 to 2022
$971k
NIDDK NIH HHS K23 DK117058NIDDK NIH HHS T32 DK007202NLM NIH HHS T15 LM011271
6 · The paper itself

Abstract

BACKGROUND &

aimsA comprehensive knowledge of the natural history of ulcerative colitis (UC) helps understand disease evolution, identify poor prognostic markers and impact of treatment strategies, and facilitates shared decision-making. We systematically reviewed the natural history of UC in adult population-based cohort studies with long-term follow-up.

methodsThrough a systematic literature review of MEDLINE through March 31, 2016, we identified 60 studies performed in 17 population-based inception cohorts reporting the long-term course and outcomes of adult-onset UC (n = 15,316 UC patients).

resultsLeft-sided colitis is the most frequent location, and disease extension is observed in 10%-30% of patients. Majority of patients have a mild-moderate course, which is most active at diagnosis and then in varying periods of remission or mild activity; about 10%-15% of patients experience an aggressive course, and the cumulative risk of relapse is 70%-80% at 10 years. Almost 50% of patients require UC-related hospitalization, and 5-year risk of re-hospitalization is ∼50%. The 5-year and 10-year cumulative risk of colectomy is 10%-15%; achieving mucosal healing is associated with lower risk of colectomy. About 50% of patients receive corticosteroids, although this proportion has decreased over time, with a corresponding increase in the use of immunomodulators (20%) and anti-tumor necrosis factor (5%-10%). Although UC is not associated with an increased risk of mortality, it is associated with high morbidity and work disability, comparable to Crohn's disease.

conclusionsUC is a disabling condition over time. Prospective cohorts are needed to evaluate the impact of recent strategies of early use of disease-modifying therapies and treat-to-target approach with immunomodulators and biologics. Long-term studies from low-incidence areas are also needed.

Indexed as

AdolescentAdrenal Cortex HormonesAdultAgedAged, 80 and overColectomyColitis, UlcerativeDisease ProgressionFemaleHospitalizationHumansIncidenceMaleMiddle AgedPrognosisRecurrenceAdrenal Cortex HormonesNatural HistoryPopulation-basedUlcerative Colitis

Identifiers

PMID28625817
PMCPMC6658168
OpenAlexW2626370788

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.